secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058191
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q1 2024 revenue $17.6M, net income $8.6M; cash runway into H2 2026
--------------------------------------------------------------------------------

- Revenue $17.6M (up from $8.8M YoY); net income $8.6M vs loss $25.1M in Q1 2023.
- Cash and equivalents $137.8M; cash runway extended into H2 2026 via $40M equity offering.
- PBGENE-HBV on track for IND/CTA filing in 2024; PBGENE-PMM expected in 2025.
- iECURE's OTC gene editing program opened enrollment in UK, first in vivo ARCUS trial.
- Regained rights to three preclinical programs (DMD, liver, CNS) from Prevail collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024058191/0000950170-24-058191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017024058191/dtil-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer